# Phase 3 sclerosis trials recruiting: 20 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 20 trials in phase 3 for sclerosis that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 3 sclerosis trials: 20 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-3/sclerosis

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 20
- Recruiting or not yet: 20
- Read on: November 19, 2026

## Trials

The 20 newest of 20, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 16, 2026 | NCT07937852 | A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants With Multiple Sclerosis (MS) | Hoffmann-La Roche | Phase 3 | Not yet recruiting | Multiple Sclerosis | 1,800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07937852) |
| November 12, 2026 | NCT07930624 | A Study to Investigate Long-term Safety and Tolerability of Frexalimab in Participants With Multiple Sclerosis | Sanofi | Phase 3 | Not yet recruiting | Multiple Sclerosis | 2,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07930624) |
| August 3, 2026 | NCT07742579 | Online Mindfulness-Based Cognitive Therapy for People With Multiple Sclerosis With Mild-Moderate Depression | Sponsor not shown (see the record) | Phase 3 | Not yet recruiting | Multiple Sclerosis | 152 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07742579) |
| June 3, 2026 | NCT07623668 | Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research | Oculis | Phase 3 | Recruiting | Optic Neuritis | 210 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07623668) |
| March 16, 2026 | NCT07472413 | Alternate Pre-med in Anti-Cluster of Differentiation 20 (CD20) Pilot Project | University of Miami | Phase 3 | Not yet recruiting | Multiple Sclerosis | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07472413) |
| February 11, 2026 | NCT07403266 | Treatment With Full-spectrum Cannabis Extract of Refractory Epilepsy Associated With Tuberous Sclerosis Complex (TSC) | Oils4Cure | Phase 3 | Recruiting | Tuberous Sclerosis Complex (TSC) | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07403266) |
| January 8, 2026 | NCT07325292 | Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple... | Sanofi | Phase 3 | Recruiting | Multiple Sclerosis | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07325292) |
| January 7, 2026 | NCT07322003 | Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS | Prilenia | Phase 3 | Recruiting | Amyotrophic Lateral Sclerosis | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07322003) |
| January 6, 2026 | NCT07321093 | A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis | Biocad | Phase 3 | Recruiting | Relapsing-remitting Multiple Sclerosis (RRMS) | 292 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07321093) |
| November 6, 2025 | NCT07225504 | A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis | Novartis Pharmaceuticals | Phase 3 | Recruiting | Secondary Progressive Multiple Sclerosis (SPMS) | 1,275 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07225504) |
| September 23, 2025 | NCT07189325 | A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting... | University Hospital, Montpellier | Phase 3 | Recruiting | Relapsing-Remitting Multiple Sclerosis (RRMS), Anti-CD20 Therapy | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07189325) |
| September 16, 2025 | NCT07174492 | Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS Patients | AB Science | Phase 3 | Not yet recruiting | Amyotrophic Lateral Sclerosis (ALS) | 412 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07174492) |
| May 15, 2025 | NCT06973629 | Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presentation in ALS (ENDURANCE... | Brainstorm-Cell Therapeutics | Phase 3 | Not yet recruiting | Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lateral Sclerosis | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06973629) |
| November 6, 2024 | NCT06675955 | An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment | Hoffmann-La Roche | Phase 3 | Recruiting | Multiple Sclerosis | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06675955) |
| May 10, 2024 | NCT06408259 | Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting... | Bristol-Myers Squibb | Phase 3 | Recruiting | Multiple Sclerosis, Relapsing-Remitting | 194 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06408259) |
| November 18, 2023 | NCT06136728 | Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis | MGH Institute of Health Professions | Phase 3 | Recruiting | Multiple Sclerosis | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06136728) |
| April 28, 2023 | NCT05834855 | Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS | Amsterdam UMC, location VUmc | Phase 3 | Recruiting | Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Demyelinating Autoimmune Diseases, CNS, Autoimmune... | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05834855) |
| March 7, 2023 | NCT05758831 | RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis. | Rennes University Hospital | Phase 3 | Recruiting | Multiple Sclerosis, Relapsing-remitting Multiple Sclerosis | 386 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05758831) |
| September 9, 2022 | NCT05534672 | Placebo Controlled Study to Assess the Efficacy and Safety of Rapamycin in Drug Resistant Epilepsy Associated With Tuberous Sclerosis... | Sponsor not shown (see the record) | Phase 3 | Recruiting | Tuberous Sclerosis Complex | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05534672) |
| April 25, 2017 | NCT03127267 | Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients | AB Science | Phase 3 | Recruiting | Amyotrophic Lateral Sclerosis | 495 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03127267) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Hoffmann-La Roche](https://specstream.ai/data/clinical-trials/company/hoffmann-la-roche) | 2 |
| [Sanofi](https://specstream.ai/data/clinical-trials/company/sanofi) | 2 |
| [AB Science](https://specstream.ai/data/clinical-trials/company/ab-science) | 2 |
| Amsterdam UMC, location VUmc | 1 |
| [Bristol-Myers Squibb](https://specstream.ai/data/clinical-trials/company/bristol-myers-squibb) | 1 |
| MGH Institute of Health Professions | 1 |
| [Biocad](https://specstream.ai/data/clinical-trials/company/biocad) | 1 |
| University Hospital, Montpellier | 1 |
| Oculis | 1 |
| University of Miami | 1 |
| Prilenia | 1 |
| Oils4Cure | 1 |
| Rennes University Hospital | 1 |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 1 |
| Brainstorm-Cell Therapeutics | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 9 |
| Spain | 6 |
| France | 6 |
| Italy | 5 |
| Poland | 5 |
| Germany | 4 |
| Belgium | 4 |
| Netherlands | 3 |
| Portugal | 3 |
| Russia | 3 |
| Israel | 3 |
| Sweden | 3 |
| Greece | 3 |
| Australia | 2 |
| Mexico | 2 |
| Romania | 2 |
| Bulgaria | 2 |
| Ukraine | 2 |
| Brazil | 2 |
| China | 2 |
| Canada | 2 |
| Ireland | 2 |
| United Kingdom | 2 |
| Denmark | 2 |
| Slovenia | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Water utilities in the United States](https://specstream.ai/data/businesses/water-utilities/united-states)
- [Dominican restaurants in the United States](https://specstream.ai/data/businesses/dominican-restaurants/united-states)
- [Metal plating companies in the United States](https://specstream.ai/data/businesses/metal-plating-companies/united-states)
- [Turkish restaurants in the United States](https://specstream.ai/data/businesses/turkish-restaurants/united-states)
- [Court reporters in the United States](https://specstream.ai/data/businesses/court-reporters/united-states)
- [Lumber stores in the United States](https://specstream.ai/data/businesses/lumber-stores/united-states)
